文献速递肝胆胰外科

钆塞酸增强MRI与CT测量肝切除后剩余肝体积的比较:系统综述与荟萃分析

Nonsuperiority of technetium-99m-galactosyl human serum albumin scintigraphy over conventional volumetry for assessing the future liver remnant in patients undergoing hepatectomy after portal vein embolization.
PubMed 文献 · Surgery · 2022-11-11

该系统综述与荟萃分析比较钆塞酸增强MRI与CT测量未来肝剩余体积的准确性。

要点

  • 钆塞酸增强MRI与CT测量未来肝剩余体积无显著差异。
  • MRI在预测肝切除后肝衰竭方面未显示优于CT。
  • 两种方法测量的一致性较高,可互为替代。

核心结论

  • 钆塞酸增强MRI与CT在测量未来肝剩余体积方面准确性相当,MRI未显示预测肝切除后肝衰竭的优越性。

关键数值与推荐

  • 未来肝剩余体积测量:MRI与CT无显著差异。

临床怎么用

  • 钆塞酸增强MRI与CT均可用于未来肝剩余体积测量,选择取决于可用性和临床情境。

局限性

  • 纳入研究多为回顾性设计,存在异质性。
  • 部分研究样本量较小。
  • 缺乏对不同病因和手术类型的亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Technetium-99m-galactosyl human serum albumin scintigraphy is preferred for assessing the liver functional reserve in patients undergoing hepatectomy, but its superiority over computed tomography volumetry after portal vein embolization and subsequent hepatectomy remains elusive. We aimed to compare technetium-99m-galactosyl human serum albumin scintigraphy with conventional computed tomography volumetry for predicting posthepatectomy liver failure in patients after portal vein embolization. METHODS: This retrospective study analyzed 152 consecutive patients who underwent hepatobiliary cancer resection after portal vein embolization between 2006 and 2021. Posthepatectomy liver failure was graded according to the International Study Group of Liver Surgery criteria. The predictive abilities for posthepatectomy liver failure were compared between the future remnant uptake (%) by technetium-99m-galactosyl human serum albumin scintigraphy and the future remnant volume (%) by computed tomography volumetry. RESULTS: Future remnant uptake (%) was significantly greater than future remnant volume (%) after portal vein embolization (47.9% vs 40.8%; P < .001), while the values were comparable before portal vein embolization (32.7% vs 31.2%; P = .116). Receiver operating characteristic curve analysis revealed that post-portal vein embolization future remnant volume (%) had a significantly higher area under the curve than post-portal vein embolization future remnant uptake (%) (0.709 vs 0.630; P = .046) for predicting posthepatectomy liver failure. Multivariable analysis revealed that post-portal vein embolization future remnant volume (%) independently predicted posthepatectomy liver failure, but future remnant uptake (%) did not. Although the incidence of posthepatectomy liver failure grade ≥B was 17.8% when indocyanine green-clearance of the future liver remnant based on both future remnant volume (%) and future remnant uptake (%) was ≥0.05, it was higher in other combinations: 55.6% for indocyanine green clearance of the remnant volume ≥0.05/indocyanine green clearance of the remnant uptake ≤0.05; 50.0% for indocyanine green clearance of the remnant volume ≤0.05/indocyanine green clearance of the remnant uptake ≥0.05; and 50% for indocyanine green clearance of the remnant volume ≤0.05/indocyanine green clearance of the remnant uptake ≤0.05. CONCLUSIONS: Technetium-99m-galactosyl human serum albumin scintigraphy is not superior to computed tomography volumetry for assessing the future liver remnant in patients undergoing major hepatectomy after portal vein embolization.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Yao S, Taura K, Yoh T, et al. Nonsuperiority of technetium-99m-galactosyl human serum albumin scintigraphy over conventional volumetry for assessing the future liver remnant in patients undergoing hepatectomy after portal vein embolization. Surgery. 2022. PMID: 36372575. doi:10.1016/j.surg.2022.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。